Temple study's pre-clinical data shows Angiocidin effective against leukemia
- Posted: December 10, 2012
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in mice by almost two-thirds in pre-clinical experiments. A researcher from Temple University’s School of Medicine who discovered Angiocidin, presented the findings during the American Society of Hematology’s national meeting in Atlanta on Dec. 9. Temple University is home to the Fox Chase Cancer Center.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.